(NP (NP (NN c-myc) (NN mRNA) (NN expression)) (PP (IN in) (NP (NP (JJ minor) (JJ salivary) (NNS glands)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NN Sjogren) (POS 's)) (NN syndrome))))))) (. .))
(S (S-COOD (S (NP-SBJ-29 (NN c-myc) (NN protooncogene)) (VP (VBZ is) (VP (VBN implicated) (NP (-NONE- *-29)) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (NN B) (NN cell) (JJ lymphoid) (NNS malignancies)))))))) (CC and) (S (NP-SBJ-31 (NP (JJ high) (NNS levels)) (PP (IN of) (NP (NN c-myc) (NN mRNA) (NN expression)))) (VP (VBP are) (VP (VBN observed) (NP (-NONE- *-31)) (PP (IN in) (NP (VBN activated) (NN blood) (JJ mononuclear) (NNS cells))))))) (. .))
(S (NP-SBJ-32 (NP (NP (NN Sjogren) (POS 's)) (NN syndrome)) (PRN (-LRB- -LRB-) (NP (NN SS)) (-RRB- -RRB-))) (VP (VBZ is) (VP (VBN characterized) (NP (-NONE- *-32)) (PP (IN by) (NP-LGS (NP (NP (JJ lymphocytic) (NNS infiltrates)) (PP (IN of) (NP (JJ exocrine) (NNS glands)))) (, ,) (NP (JJ remarkable) (NN B) (NN cell) (NN hyperreactivity)) (CC and) (NP (NP (DT a) (JJ strong) (NN predisposition)) (PP (TO to) (NP (NN B) (NN cell) (NN neoplasia)))))))) (. .))
(S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP-SBJ-33 (NP (NN c-myc) (NN protooncogene) (NN mRNA) (NN expression)) (PP (IN in) (NP (NP (CD 29) (JJ labial) (JJ minor) (JJ salivary) (NN gland) (NNS biopsies)) (PP (IN from) (NP-COOD (NP (NP (NNS patients)) (PP (IN with) (NP (JJ primary) (NNS SS)))) (CC and) (NP (CD 15) (NNS controls))))))) (VP (VBD was) (VP (VBN examined) (NP (-NONE- *-33)) (S (NP-SBJ (-NONE- *)) (VP (VBG using) (NP (ADJP (FW in) (FW situ)) (NN hybridization) (NN histochemistry)))))) (. .))
(S (NP-SBJ-35 (NP (CD Two) (JJ 40mer) (NNS oligonucleotides)) (PP (IN from) (NP (NP (NP-COOD (NP (DT the) (JJ 1st) (NP (-NONE- *RNR*-34))) (CC and) (NP (DT the) (JJ 2nd) (NP (-NONE- *RNR*-34)))) (NP-34 (NN exon))) (PP (IN of) (NP (DT the) (NN c-myc) (NN gene))))) (, ,) (VP (VBN labeled) (NP (-NONE- *)) (PP (IN with) (NP (NN 35S)))) (, ,)) (VP (VBD were) (VP (VBN used) (NP (-NONE- *-35)) (PP (IN as) (NP (NNS probes))))) (. .))
(S (S-ADV (NP-SBJ (-NONE- *)) (VP (TO To) (VP (VB detect) (NP (NP (DT the) (NN origin)) (PP (IN of) (NP (NP (DT the) (NN cell)) (VP (VBN hybridized) (NP (-NONE- *)) (PP (IN with) (NP (DT a) (NN c-myc) (NN probe)))))))))) (, ,) (NP-SBJ-37 (DT a) (JJ combined) (NN immunochemistry) (ADJP (FW in) (FW situ)) (NN hybridization) (NN histochemistry) (NN technique)) (VP (VBD was) (VP (VBN used) (NP (-NONE- *-37)))) (. .))
(S (NP-SBJ-36 (JJ High) (NN c-myc) (NN mRNA) (NN expression)) (VP (VBD was) (VP (VBN detected) (NP (-NONE- *-36)) (PP (IN on) (NP (JJ acinar) (JJ epithelial) (NNS cells))))) (. .))
(S (NP-SBJ (NN c-myc)) (VP (VBD did) (RB not) (VP (VB correlate) (PP (IN with) (NP (NP-COOD (NP (NN c-fos)) (CC and) (NP (NN c-jun))) (NN protein) (NN expression))))) (. .))
(S (NP-SBJ-38 (JJR Stronger) (NN c-myc) (NN mRNA) (NN expression)) (VP (VBD was) (VP (VBN detected) (NP (-NONE- *-38)) (PP (IN in) (NP (NP (JJ labial) (JJ salivary) (NNS glands)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP-COOD (NP (NP (JJR longer) (NN disease) (NN duration)) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN p)) (NP-PRD (QP (JJR less) (IN than) (CC or) (JJ equal) (TO to) (CD 0.002)))) (-RRB- -RRB-))) (CC and) (NP (NP (ADJP (RBR more) (JJ intense)) (NN T) (NN lymphocyte) (NNS infiltrates)) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN p)) (NP-PRD (QP (JJR less) (IN than) (CD 0.05)))) (-RRB- -RRB-))))))))) (SBAR (IN although) (S (NP-SBJ (DT these) (NNS patients)) (VP (VBD revealed) (NP-PRD (DT no) (NN hypergammaglobulinemia))))))) (. .))
(S (NP-SBJ-40 (DT No) (NN correlation)) (VP (VBD was) (VP (VBN observed) (NP (-NONE- *-40)) (PP (IN between) (NP-COOD (NP (NN c-myc) (NN mRNA)) (CC and) (NP (NN B) (NN lymphocyte) (NP-COOD (NP (NN monoclonicity)) (CC or) (NP (NN lymphoma)))))))) (. .))
(S (PP (IN In) (NP (NN conclusion))) (, ,) (NP-SBJ-41 (JJ strong) (NN c-myc) (NN mRNA) (NN expression)) (VP (VBD was) (VP (VBN observed) (NP (-NONE- *-41)) (PP (IN on) (NP (NP (JJ epithelial) (NNS cells)) (PP (IN of) (NP (NP (JJ labial) (JJ salivary) (NNS glands)) (PP (IN from) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ primary) (NN SS))))))))))) (. .))
(S (NP-SBJ (PRP$ Our) (NNS findings)) (VP (MD may) (VP (VB indicate) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (DT a) (VBN reactivated) (NN virus)) (VP (VBN hosted) (NP (-NONE- *)) (PP (IN in) (NP (DT these) (NNS cells))))))))) (. .))
